Anti-CD19 UCAR-NK cells（920th Hospital of Joint Logistics Support Force of People's Liberation Army of China）

N/A

Report date: 2022/12/24 20:00:29

Base Information

Drug NameAnti-CD19 UCAR-NK cells（920th Hospital of Joint Logistics Support Force of People's Liberation Army of China）
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy > Universal CAR-NK cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell > Chimeric antigen receptor CIK cell therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesThe 920th Hospital Of Joint Logistics Support Force Of PLA
China Registration ClassN/A

Develop Information

Active CompaniesThe 920th Hospital Of Joint Logistics Support Force Of PLA
Inactive CompaniesN/A
Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A